P/E ratio for AtriCure (ATRC)
P/E ratio as of April 2024 (TTM): -42.4
According to AtriCure's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -42.4074. At the end of 2022 the company had a P/E ratio of -43.9.
P/E ratio history for AtriCure from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -43.9 | -170.15% |
| 2021 | 62.6 | -229.4% |
| 2020 | -48.4 | 38.48% |
| 2019 | -35.0 | -28.03% |
| 2018 | -48.6 | 121.02% |
| 2017 | -22.0 | 17.91% |
| 2016 | -18.6 | -21.1% |
| 2015 | -23.6 | -25.44% |
| 2014 | -31.7 | -5.02% |
| 2013 | -33.4 | 122.38% |
| 2012 | -15.0 | -54.05% |
| 2011 | -32.6 | -20.53% |
| 2010 | -41.1 | 668.55% |
| 2009 | -5.35 | 70.95% |
| 2008 | -3.13 | -79.73% |
| 2007 | -15.4 | 94.95% |
| 2006 | -7.91 | 146.76% |
| 2005 | -3.21 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.5 | -124.71% | 🇺🇸 USA |
 Medtronic MDT | 29.5 | -169.55% | 🇮🇪 Ireland |
 Abiomed ABMD | 64.8 | -252.80% | 🇺🇸 USA |
 Boston Scientific BSX | 82.2 | -293.94% | 🇺🇸 USA |
 Edwards Lifesciences EW | 38.0 | -189.51% | 🇺🇸 USA |
 Teleflex TFX | 24.5 | -157.76% | 🇺🇸 USA |
 Cooper Companies COO | 16.5 | -138.96% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.